FACCHINETTI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 370
EU - Europa 288
AS - Asia 65
Totale 723
Nazione #
US - Stati Uniti d'America 365
SE - Svezia 156
IT - Italia 63
CN - Cina 49
DE - Germania 28
AT - Austria 18
GB - Regno Unito 6
TR - Turchia 6
CA - Canada 5
FI - Finlandia 4
FR - Francia 3
IE - Irlanda 3
IN - India 3
BE - Belgio 2
IL - Israele 2
JP - Giappone 2
KH - Cambogia 2
UA - Ucraina 2
HK - Hong Kong 1
LU - Lussemburgo 1
NL - Olanda 1
RU - Federazione Russa 1
Totale 723
Città #
Chandler 177
Ann Arbor 35
Princeton 23
Bremen 20
Vienna 18
Dearborn 14
Des Moines 12
Parma 12
Wilmington 11
Beijing 8
Nanjing 8
Izmir 5
Busseto 4
Changsha 4
Helsinki 4
Kunming 4
Nanchang 4
Pavia 4
Fremont 3
Grafing 3
Hebei 3
Jinan 3
Milan 3
Nanning 3
Redwood City 3
Woodbridge 3
Ashburn 2
Brussels 2
Candiac 2
Fairfield 2
Guangzhou 2
Hanover 2
Houston 2
Jiaxing 2
Minerbio 2
Norwalk 2
Reggio Emilia 2
Trento 2
Andover 1
Bangalore 1
Boardman 1
Bologna 1
Borås 1
Cambridge 1
Dolianova 1
Hangzhou 1
Hefei 1
Kingston 1
Kocaeli 1
Lanzhou 1
Los Angeles 1
Luxembourg 1
Macomer 1
Ningbo 1
Pavullo Nel Frignano 1
Redmond 1
Rockville 1
Saint Petersburg 1
San Mateo 1
Shanghai 1
Shenyang 1
Wuhan 1
Totale 439
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 83
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 79
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 51
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 44
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 41
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 39
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 35
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 35
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 33
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 33
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 30
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 29
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 26
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 25
Cystic brain metastases and RET fusion in lung cancer 25
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 24
Exploring the role of respiratory microbiome in lung cancer: A systematic review 23
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 23
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 23
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 21
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 20
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 20
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 10
Totale 772
Categoria #
all - tutte 1872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1872


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20188 0000 00 00 0404
2018/201948 0160 1712 02 2161
2019/202097 211526 1212 116 4503
2020/202164 1048 75 18 13692
2021/2022150 22029 23 277 96756
2022/2023402 81763856 4577 290 0000
Totale 772